Now Reading: US FDA approves Moderna’s first mRNA seasonal flu vaccine
-
01
US FDA approves Moderna’s first mRNA seasonal flu vaccine
US FDA approves Moderna’s first mRNA seasonal flu vaccine
The Story in Brief
The U.S. Food and Drug Administration has approved Moderna’s mFlusiva seasonal flu vaccine for adults aged 50 and older. It received traditional approval for people aged 50 to 64 and accelerated approval for those aged 65 and above. Moderna must conduct another study and submit further data for older adults.
The decision followed a late-stage trial of more than 40,000 adults, in which the vaccine was 26.6% more effective than a standard-dose flu vaccine. Separate data showed stronger antibody responses than Sanofi’s high-dose vaccine among older adults. The shot is unlikely to generate major revenue before the second half of 2027. It uses mRNA technology, which could support quicker updates to match circulating flu strains.
The Indian Opinion
The approval offers another option for older adults and may advance mRNA vaccine technology. However, the accelerated approval for those aged 65 and above means further evidence is still required. Claims that the vaccine will quickly transform flu prevention or revive Moderna’s finances should be treated cautiously. The reported trial results are encouraging, but real-world performance, safety monitoring and public acceptance will matter over time.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
